Biotech Firm Loyal Advances First FDA-Approved Lifespan Extension Drug for Senior Dogs

Biotechnology company Loyal is developing LOY-002, a pioneering longevity drug designed as a daily pill for senior dogs. The medication targets metabolic drivers of aging to delay disease onset and extend healthy lifespan in canines over 10 years old weighing at least 14 pounds. In January 2026, the FDA accepted Loyal's Target Animal Safety technical section, marking significant progress toward approval. This submission included safety data from over 400 dogs participating in the STAY effectiveness trial. Loyal completed its Reasonable Expectation of Effectiveness requirement in early 2025, achieving two of three major technical sections needed for market launch. The company anticipates completing the final technical section by 2027. If successful, LOY-002 would become the first FDA-approved drug for lifespan extension in any species, operating on principles of caloric restriction mimicry to alter cellular energy processing.